Yee Lee Cheah, Mary Ann Simpson, James J. Pomposelli, Elizabeth A. Pomfret – 21 November 2012 – The incidence of morbidity and mortality after living donor liver transplantation (LDLT) is not well understood because reporting is not standardized and relies on single‐center reports. Aborted hepatectomies (AHs) and potentially life‐threatening near‐miss events (during which a donor's life may be in danger but after which there are no long‐term sequelae) are rarely reported. We conducted a worldwide survey of programs performing LDLT to determine the incidence of these events.

Gang Zheng, Long Jiang Zhang, Yue Cao, Guang Ming Lu – 21 November 2012

Tatyana V. Masyuk, Brynn N. Radtke, Angela J. Stroope, Jesús M. Banales, Sergio A. Gradilone, Bing Huang, Anatoliy I. Masyuk, Marie C. Hogan, Vicente E. Torres, Nicholas F. LaRusso – 21 November 2012 – In polycystic liver (PLD) and kidney (PKD) diseases, increased cyclic adenosine monophosphate (cAMP) levels trigger hepatorenal cystogenesis. A reduction of the elevated cAMP by targeting somatostatin receptors (SSTRs) with octreotide (OCT; a somatostatin analog that preferentially binds to SSTR2) inhibits cyst growth.

Emre Turer, Don C. Rockey, Amit G. Singal – 21 November 2012

Khayriyyah Mohd Hanafiah, Justina Groeger, Abraham D. Flaxman, Steven T. Wiersma – 21 November 2012 – In efforts to inform public health decision makers, the Global Burden of Diseases, Injuries, and Risk Factors 2010 (GBD2010) Study aims to estimate the burden of disease using available parameters. This study was conducted to collect and analyze available prevalence data to be used for estimating the hepatitis C virus (HCV) burden of disease.

Patrizia Burra, Eleonora De Martin, Stefano Gitto, Erica Villa – 21 November 2012 – Women constitute a particular group among patients with chronic liver disease and in the post–liver transplantation (LT) setting: they are set apart not only by traditional differences with respect to men (ie, body mass index, different etiologies of liver disease, and accessibility to transplantation) but also by factors related to hormonal changes that characterize first the fertile age and subsequently the postmenopausal period (eg, disease course variability and responses to therapy).

Jaana Helenius‐Hietala, Hellevi Ruokonen, Lisa Grönroos, Harri Rissanen, Liisa Suominen, Helena Isoniemi, Jukka H. Meurman – 21 November 2012 – Recipients of liver transplantation (LT) receive lifelong immunosuppression, which causes side effects. We investigated self‐reported oral symptoms and associated risk factors with the following hypothesis: symptoms and signs would differ between LT recipients of different etiology groups and also between LT recipients and a control population.

Sumihito Tamura, Yasuhiko Sugawara, Norihiro Kokudo – 21 November 2012

Mureo Kasahara, Seisuke Sakamoto, Takanobu Shigeta, Hajime Uchida, Ikumi Hamano, Hiroyuki Kanazawa, Megumi Kobayashi, Toshihiro Kitajima, Akinari Fukuda, Mohamed Rela – 21 November 2012 – Liver transplantation is now an established treatment for children with end‐stage liver disease. Left lateral segment (LLS) grafts are most commonly used in split and living donor liver transplantation in children. In very small children, LLS grafts can be too large, and further nonanatomical reduction has recently been introduced to mitigate the problem of large‐for‐size grafts.

Tao Wei, Yi Lv – 21 November 2012